Test Price
1,000 AED✅ Home Collection Available
C-KIT Mutation Screening (Exons 9, 11, 13, 17) for AML in UAE | 1000 AED | DHA Licensed
Executive Summary & Core Metrics
Clinical Highlights
- 99.9% Diagnostic Sensitivity — ISO 9001:2015 accredited Sanger sequencing delivers per‑base accuracy for actionable KIT variants.
- VIP Mobile Phlebotomy & Cold‑Chain Transport — Home collection available daily from 8 AM to 11 PM with temperature‑controlled logistics.
- Post‑Test Clinical Guidance — Telephonic explanation of results by a DHA‑licensed clinician.
- Direct Insurance Billing Verification — WhatsApp +971 54 548 8731.
Test Overview & Methodology
The C‑KIT mutation screening (exons 9, 11, 13, 17) is a molecular diagnostic test that identifies acquired variants in the KIT gene directly informing targeted therapy selection in acute myeloid leukaemia (AML) and related myeloid neoplasms. The method employed is bidirectional Sanger sequencing, the gold standard for single‑exon resolution, validated under ISO 9001:2015 quality management.
| Feature | Our Test (This Page) | Closest Alternative |
|---|---|---|
| Precision | Gold‑standard Sanger Sequencing with 99.9% per‑base accuracy | NGS panels may cover broader regions but with lower single‑exon resolution |
| Method | Bidirectional Sanger Sequencing, ISO‑validated | Targeted NGS; results often require orthogonal confirmation |
| Speed | 7–8 working days, UAE‑based lab | 10–14 days (international send‑outs) |
| Regulatory Compliance | DHA‑licensed (Facility: 1143), ISO 9001:2015, UAE PDPL & Federal Law No. 2 of 2019 | Variable; may not reference local data protection laws |
Physician Insight & Safety Protocols
“As a Specialist Diagnostic Radiologist at DNA Labs UAE, I interpret C‑KIT mutations alongside imaging and haematopathological findings to guide targeted therapy. A positive result can indicate a targetable driver for tyrosine kinase inhibitors, but a negative finding does not rule out other actionable mutations. This test should be used as part of a comprehensive diagnostic workup.” — Mr. Prabhakar Reddy Kalathoor, DHA Licence: 61713011
Advisory: Medication Safety & Test Preparation
⚠ Do not discontinue any prescribed medication (including chemotherapy or targeted agents) without consulting your doctor.
No special preparation is required for the blood draw. Inform your healthcare provider of all medications and supplements you are taking.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active uncontrolled infection or significant haemodynamic instability. For surgery, pregnancy, or travel abroad cases, a physician prescription is not required; all other cases need a valid doctor’s prescription.
- ER Red Flags: Severe bleeding, high fever (>38.5°C), sudden confusion, or chest pain – proceed to the nearest emergency department immediately. Do not wait for test results.
- This test is not a standalone diagnostic tool; it complements bone marrow biopsy and clinical evaluation.
Patient FAQ & Clinical Guidance
1. What does a C‑KIT mutation mean for my AML treatment?
A C‑KIT mutation identifies a targetable driver that makes your leukaemia cells susceptible to tyrosine kinase inhibitors like midostaurin, guiding precision therapy selection. This test helps your oncologist decide on the most effective targeted approach.
2. How is the sample collected and is it painful?
A standard peripheral blood draw is all that is required. Our VIP mobile phlebotomy service ensures minimal discomfort with rapid, cold‑chain transport to the laboratory.
3. Can this test be performed on children or during pregnancy?
Yes, with appropriate clinical justification and parental consent for minors (as per Federal Decree‑Law No. 4 of 2016 on Medical Liability). For pregnant patients or travellers, a physician prescription is not required, but all cases must be co‑managed by a specialist.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the following legal frameworks:
- DHA Facility License No. 1143 – fully compliant with Dubai Health Authority standards.
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensures your health data is processed lawfully, transparently, and securely.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governs electronic health records and telemedicine.
- ISO 9001:2015 Quality Management – accredited for laboratory processes and cold‑chain logistics.
Clinical & Logistical Metadata
| Test Name | C-KIT Mutation Screening (Exons 9, 11, 13, 17) |
| Price (AED) | 1,000 AED |
| Turnaround Time | 7–8 working days |
| Sample Type / Matrix | Peripheral Blood (VIP Mobile Phlebotomy available) |
| Methodology Used | Bidirectional Sanger Sequencing |
| ICD-10-CM Code | C92.00 |
| LOINC Code | 94218-1 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians